Want to see TSE:IZO full AI Analyst Report?
IZO Stock Chart & Stats
C$0.23
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.23
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.19 - C$0.49
Previous CloseN/A
Volume4.00K
Average Volume (3M)17.40K
Market Cap
C$13.25M
Enterprise ValueC$19.25
Total Cash (Recent Filing)C$219.71K
Total Debt (Recent Filing)C$3.11M
Price to Earnings (P/E)―
Beta-0.14
Next Earnings
Sep 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding69,724,680
10 Day Avg. Volume14,206
30 Day Avg. Volume17,399
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)-3.74
Price to Sales (P/S)0.00
P/FCF Ratio-24.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Breast-Imaging PlatformA dedicated breast-imaging platform gives Izotropic a clearly defined product focus within medical diagnostics. If the system achieves clinical commercialization, this specialization could support concentrated development, targeted customer engagement, and a distinct position in breast cancer evaluation over the next several quarters.
Moderating Cash BurnThe substantial reduction in operating cash outflows indicates improved spending discipline compared with the peak-burn years. Although cash flow remains negative, sustained control of operating expenses could extend available resources and provide a more stable base for continued product development.
Lower Recent Net LossesNet losses remain material, but the improvement from the 2022–2023 peak suggests some expense control and a lower ongoing loss burden. Maintaining this improvement would reduce the rate of resource consumption and could strengthen the company’s ability to pursue commercialization initiatives.
Bears Say
No Reported RevenueThe absence of reported revenue over multiple years means Izotropic has not yet demonstrated commercial traction or validated its intended clinical-market revenue model. Continued pre-revenue operation leaves profitability dependent on future commercialization rather than an established source of operating income.
Negative Equity And Rising DebtNegative equity combined with rising debt materially weakens financial flexibility and increases dependence on financing. The deterioration also leaves limited capacity to absorb continued losses or fund development internally, making balance-sheet repair an important constraint on the company’s medium-term execution.
Persistent Negative Free Cash FlowPersistent operating and free-cash-flow deficits show that the business is not yet self-funding, despite the earlier moderation in operating burn. Continued negative cash generation can require external capital to support operations and product development, increasing financing pressure while revenue remains absent.
Izotropic News
IZO FAQ
What was Izotropic Corp.’s price range in the past 12 months?
Izotropic Corp. lowest stock price was C$0.19 and its highest was C$0.49 in the past 12 months.
What is Izotropic Corp.’s market cap?
Izotropic Corp.’s market cap is C$13.25M.
When is Izotropic Corp.’s upcoming earnings report date?
Izotropic Corp.’s upcoming earnings report date is Sep 30, 2026 which is in 7 days.
How were Izotropic Corp.’s earnings last quarter?
Izotropic Corp. released its earnings results on Mar 27, 2026. The company reported -C$0.004 earnings per share for the quarter.
Is Izotropic Corp. overvalued?
According to Wall Street analysts Izotropic Corp.’s price is currently Overvalued.
Does Izotropic Corp. pay dividends?
Izotropic Corp. does not currently pay dividends.
What is Izotropic Corp.’s EPS estimate?
Izotropic Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Izotropic Corp. have?
Izotropic Corp. has 69,724,680 shares outstanding.
What happened to Izotropic Corp.’s price movement after its last earnings report?
Izotropic Corp. reported an EPS of -C$0.004 in its last earnings report. Following the earnings report the stock price went down -2.128%.
Which hedge fund is a major shareholder of Izotropic Corp.?
Currently, no hedge funds are holding shares in TSE:IZO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Izotropic Corp.
Izotropic Corporation operates as a MedTech enterprise, concentrating on the commercialization of diagnostic solutions for breast cancer. Their primary focus lies in developing and offering a breast CT imaging system alongside a 3D CT breast imaging platform, both specifically designed to enable earlier detection and more accurate diagnosis of the disease. Established in 2016, the company maintains its corporate base in Surrey, Canada.
Technical Analysis
Spectral Medical
―
BioMark Diagnostics
―
Perimeter Medical Imaging AI
―
Sona Nanotech Inc
―
VentriPoint Diagnostics
―